Diagante is a biotechnology startup that aims to revolutionize in vitro diagnostics with its innovative solution. Founded in 2019, the company focuses on unlocking the potential of solid samples in the field of biological diagnostics. Its platform enables the analysis of solid clinical specimens on rapid and high-throughput instruments in clinical pathology labs, promising faster results, enhanced personalized medical care, and lower costs for all stakeholders. With a focus on biotechnology, health care, and medical devices, Diagante has positioned itself in an industry with immense potential for growth and impact.
There is no investment information
No recent news or press coverage available for Diagante.